JP2022153392A5 - - Google Patents

Download PDF

Info

Publication number
JP2022153392A5
JP2022153392A5 JP2022106421A JP2022106421A JP2022153392A5 JP 2022153392 A5 JP2022153392 A5 JP 2022153392A5 JP 2022106421 A JP2022106421 A JP 2022106421A JP 2022106421 A JP2022106421 A JP 2022106421A JP 2022153392 A5 JP2022153392 A5 JP 2022153392A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
tumor
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022106421A
Other languages
English (en)
Japanese (ja)
Other versions
JP7400025B2 (ja
JP2022153392A (ja
Filing date
Publication date
Priority claimed from US15/814,105 external-priority patent/US9938288B1/en
Priority claimed from PCT/US2018/025887 external-priority patent/WO2018187331A1/en
Application filed filed Critical
Publication of JP2022153392A publication Critical patent/JP2022153392A/ja
Publication of JP2022153392A5 publication Critical patent/JP2022153392A5/ja
Priority to JP2023206236A priority Critical patent/JP7696416B2/ja
Application granted granted Critical
Publication of JP7400025B2 publication Critical patent/JP7400025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022106421A 2017-04-05 2022-06-30 大環状化合物およびその使用 Active JP7400025B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023206236A JP7696416B2 (ja) 2017-04-05 2023-12-06 大環状化合物およびその使用

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762482030P 2017-04-05 2017-04-05
US62/482,030 2017-04-05
US201762526677P 2017-06-29 2017-06-29
US62/526,677 2017-06-29
US201762586416P 2017-11-15 2017-11-15
US15/814,105 2017-11-15
US62/586,416 2017-11-15
US15/814,105 US9938288B1 (en) 2017-04-05 2017-11-15 Macrocyclic compound and uses thereof
PCT/US2018/025887 WO2018187331A1 (en) 2017-04-05 2018-04-03 Macrocyclic compound and uses thereof
JP2019555001A JP7168580B2 (ja) 2017-04-05 2018-04-03 大環状化合物およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019555001A Division JP7168580B2 (ja) 2017-04-05 2018-04-03 大環状化合物およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023206236A Division JP7696416B2 (ja) 2017-04-05 2023-12-06 大環状化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2022153392A JP2022153392A (ja) 2022-10-12
JP2022153392A5 true JP2022153392A5 (https=) 2023-06-14
JP7400025B2 JP7400025B2 (ja) 2023-12-18

Family

ID=63104288

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019555001A Active JP7168580B2 (ja) 2017-04-05 2018-04-03 大環状化合物およびその使用
JP2018071700A Active JP6366873B1 (ja) 2017-04-05 2018-04-03 大環状化合物およびその使用
JP2022106421A Active JP7400025B2 (ja) 2017-04-05 2022-06-30 大環状化合物およびその使用
JP2023206236A Active JP7696416B2 (ja) 2017-04-05 2023-12-06 大環状化合物およびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019555001A Active JP7168580B2 (ja) 2017-04-05 2018-04-03 大環状化合物およびその使用
JP2018071700A Active JP6366873B1 (ja) 2017-04-05 2018-04-03 大環状化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023206236A Active JP7696416B2 (ja) 2017-04-05 2023-12-06 大環状化合物およびその使用

Country Status (34)

Country Link
US (2) US11725015B2 (https=)
EP (2) EP4119563A3 (https=)
JP (4) JP7168580B2 (https=)
KR (2) KR102836514B1 (https=)
CN (2) CN110831946B (https=)
AU (2) AU2018250147B2 (https=)
CA (1) CA3056945A1 (https=)
CL (1) CL2019002854A1 (https=)
CO (1) CO2019011538A2 (https=)
DK (1) DK3606928T3 (https=)
EC (1) ECSP19075677A (https=)
ES (1) ES2931533T3 (https=)
HR (1) HRP20221385T1 (https=)
HU (1) HUE060466T2 (https=)
IL (2) IL288991B2 (https=)
JO (1) JOP20190234B1 (https=)
LT (1) LT3606928T (https=)
MA (1) MA48027B1 (https=)
MD (1) MD3606928T2 (https=)
MX (1) MX389899B (https=)
NZ (2) NZ757372A (https=)
PE (1) PE20200602A1 (https=)
PH (1) PH12019502197A1 (https=)
PL (1) PL3606928T3 (https=)
PT (1) PT3606928T (https=)
RS (1) RS63755B1 (https=)
SA (1) SA519410259B1 (https=)
SG (1) SG11201908603PA (https=)
SI (1) SI3606928T1 (https=)
SM (1) SMT202200455T1 (https=)
TW (3) TWI781163B (https=)
UA (1) UA124399C2 (https=)
WO (1) WO2018187331A1 (https=)
ZA (1) ZA201906279B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
SMT202200455T1 (it) * 2017-04-05 2023-01-13 Harvard College Composto macrociclico e relativi usi
WO2019010363A1 (en) * 2017-07-06 2019-01-10 President And Fellows Of Harvard College HALICHONDRINES SYNTHESIS
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019099646A1 (en) * 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) * 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 7−チアプロスタグランジン類およびその製造法
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20060154312A1 (en) 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CN101657990B (zh) 2007-03-07 2014-03-19 交互数字技术公司 用于产生和处理MAC-ehs协议数据单元的方法和设备
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
CN101910180A (zh) 2007-11-16 2010-12-08 卫材R&D管理有限公司 用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应
CA2720632C (en) 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドAlphora Research Inc. 3−((2s,5s)−4−メチレン−5−(3−オキソプロピル)テトラヒドロフラン−2−イル)プロパノール誘導体およびそれらの有用な中間体を調製する方法
CA2860446C (en) 2011-12-29 2017-01-10 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
SG11201404432QA (en) * 2012-11-30 2014-10-30 Hangzhou Zylox Pharma Co Ltd Rafamycin analogs and methods for making same
CA2909209A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
EP3016957A4 (en) 2013-07-03 2016-11-30 Alphora Res Inc SYNTHETIC METHOD FOR THE PRODUCTION OF CYCLIC C1-KETO ANALOGUE OF HALICHONDRIN B AND USEFUL INTERMEDIATE PRODUCTS, INCLUDING INTERMEDIATE PRODUCTS WITH -SO2- (P-TOLYL) GROUPS
BR112016009452B1 (pt) 2013-11-04 2022-06-07 Eisai R&D Management Co., Ltd Métodos de preparar intermediários na síntese de eribulina, métodos de preparar eribulina e mesilato de eribulina, e compostos intermediários
EP3077399B1 (en) 2013-12-06 2019-02-20 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX392296B (es) 2015-05-07 2025-03-24 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
US10562859B2 (en) * 2015-07-01 2020-02-18 Signalchem Lifesciences Corporation Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
EP3582804A1 (en) 2017-02-20 2019-12-25 Polyphor Ag Pharmaceutical combinations for treating cancer
SMT202200455T1 (it) * 2017-04-05 2023-01-13 Harvard College Composto macrociclico e relativi usi
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019009956A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College SUMMARY OF MEDIUM MEDIATED KETONE
US20230135188A1 (en) 2017-07-06 2023-05-04 President And Fellows Of Harvard College Fe/cu-mediated ketone synthesis
WO2019010363A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College HALICHONDRINES SYNTHESIS
WO2019099646A1 (en) * 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2022019921A1 (en) 2020-07-24 2022-01-27 President And Fellows Of Harvard College Ketone synthesis and applications

Similar Documents

Publication Publication Date Title
JP2022153392A5 (https=)
JP2023512039A5 (https=)
JP2023168298A5 (https=)
JP2007523862A5 (https=)
JP2021534158A5 (https=)
JP2021534168A5 (https=)
JP2023500483A5 (https=)
RU2016132759A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
JP2020522521A5 (https=)
JP2020527139A5 (https=)
CN112888458A (zh) Cldn18的抗体和化疗药物的联合治疗
RU2020113749A (ru) Аналоги таиланстатина
JP2024512775A5 (https=)
JP2019529476A5 (https=)
RU2016112421A (ru) Протиоопухолевое средство и усилитель противоопухолевого эффекта
GEAP202416383A (en) Use of medicament in treatment of tumor disease
Eskander et al. Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise
JP2022551672A5 (https=)
JP2023515687A5 (https=)
CA2454664A1 (en) Cancer treatment with go6976 and its related compounds
Jakobsson et al. Variations in radiosensitivity of various types of malignant salivary—gland tumour
Kolagatla et al. Colorectal adenocarcinoma metastasis to the hard palate: An uncommon site of metastasis for a common malignancy
JP2020533368A5 (https=)
JPWO2023048231A5 (https=)
Yasuyama et al. Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection